【摘要】 目的研究盐酸多奈哌齐联合奥拉西坦在治疗帕金森病痴呆患者中的临床疗效及用药安全。方法方便选取2020年6月—2021年5月该院收治的112例帕金森病痴呆患者,根据临床用药分类,均分两组,单药组与联合组。单药组给予奥拉西坦治疗,联合组在此基础上加用盐酸多奈哌齐。对比两组同一疗程后简易精神状态量表(MMSE)、蒙特利尔认知评估(MoCA)、日常生活能力(ADL)的评分数据,血清CRP、PARK7、NT3水平数据,以及用药期间不良反应发生率。结果治疗后,单药组MMSE、MoCA、ADL评分为(21.33±3.02)分、(20.17±1.99)分、(70.22±9.69)分,联合组MMSE、MoCA、ADL评分为(26.21±3.56)分、(24.01±2.63)分、(84.35±8.48)分,两组比较,差异有统计学意义(t=7.822、8.713、8.212,P<0.05)。治疗后,联合组CRP、PARK7的指标数据明显低于单药组,而NT3指标均值则明显高于单药组,差异有统计学意义(t=34.490、28.066、20.868,P<0.05)。联合组用药不良反应发生率为5.36%,单药组为8.93%,两组比较,差异无统计学意义(t=0.538,P>0.05)。结论针对帕金森病痴呆患者,临床用药可首选盐酸多奈哌齐联合奥拉西坦的用药方案,对于患者提升认知能力,恢复精神状态与生活能力,效果更佳,且不良反应较低,安全可靠,可推荐临床用药。更多还原

【Abstract】 Objective To study the clinical efficacy and drug safety of donepezil hydrochloride combined with oxiracetam in the treatment of patients with Parkinson’s disease dementia. Methods Conveniently selected 112 patients with Parkinson’s disease dementia admitted to the hospital from June 2020 to May 2021. According to the classification of clinical medications, they were divided into two groups,single-drug group and combined group. Oxiracetam was given to the singledrug group, and donepezil hydrochloride was added to the combined group on this basis. Compared the scoring data of simplified mental state scale(MMSE), montreal cognitive assessment(MoCA), daily living ability(ADL), serum CRP,PARK7, NT3 levels, and the incidence of adverse reactions during the same course of treatment between the two groups after the same course of treatment. Results After treatment, the scores of MMSE, MoCA, and ADL in the single-drug group were(21.33±3.02)points,(20.17±1.99)points,(70.22±9.69)points, and the scores of MMSE, MoCA, and ADL in the combined group were(26.21 ±3.56)points,(24.01 ±2.63)points,(84.35 ±8.48)points, Compared the two groups, the difference was statistically significant(t =7.822, 8.713, 8.212,P <0.05). After treatment, the index data of CRP and PARK7 in the combination group were significantly lower than that of the single-drug group, while the mean value of NT3 index was significantly higher than that of the single-drug group, the difference was statistically significant(t=34.490, 28.066, 20.868,P<0.05). Incidence of a adverse drug reactions were 5.36% in the combination group and 8.93% in the single-drug group,compared between the two groups, the difference was not statistically significant(χ2=0.538, P >0.05). Conclusion For patients with Parkinson’s disease dementia, the first choice for clinical medication is donepezil hydrochloride combined with Oxiracetam. It has better effect for patients to improve their cognitive ability, restore their mental state and life ability,and has low adverse reactions, and is safe and reliable, which may be recommended for clinical medication.更多还原